ARTV · Stock research · Public disclosure research

ARTV Insider Trading Activity

Artiva Biotherapeutics, Inc.

Data as of Nov 18, 2026. Collected disclosures, not exhaustive history.

30-day and 12-month windows end Nov 22, 2026 and use transaction dates, not disclosure dates. The data-as-of date above reflects the latest collected disclosure and may be older than the window end.

Insider buys · 30d0Collected open-market purchases
Insider sales · 30d9Collected sales
Net reported value · 30d-$987,430.00Reported purchase value less reported sale value, trailing 30 days.
Distinct insiders · 30d5In collected disclosures
Latest Form 4Nov 18, 2026Collected filing date, not trade date

For transactions dated in the 30-day window ending Nov 22, 2026, collected disclosures for Artiva Biotherapeutics, Inc. (ARTV) show 9 sales by insiders. Net reported purchase less sale value is -$987,430.00.

Collected insider transactions

9 collected transactions in the trailing 12 months. Open-market purchases and sales appear first by default, newest first within each group. Values are reported, not estimates. Derivative transactions are labeled separately.
Bush JenniferCOO, CLO, Compliance OfficerOpen-market saleNon-derivative security10b5-1: —19,217$3.91$75,175.00338,503Nov 17, 2026Nov 18, 2026Source record
Horan ChristopherChief Tech Operations OfficerOpen-market saleNon-derivative security10b5-1: —20,546$3.91$80,374.00281,775Nov 17, 2026Nov 18, 2026Source record
Miralles Gines DiegoPresident & Head of R&DOpen-market saleNon-derivative security10b5-1: —1,043$3.91$4,080.00121,457Nov 17, 2026Nov 18, 2026Source record
Aslan FredCEOOpen-market saleNon-derivative security10b5-1: —119,771$3.91$468,532.001,337,657Nov 17, 2026Nov 18, 2026Source record
Banerjee SubhashisChief Medical OfficerOpen-market saleNon-derivative security10b5-1: —4,037$3.91$15,792.00164,701Nov 17, 2026Nov 18, 2026Source record
Bush JenniferCOO, CLO, Compliance OfficerOpen-market saleNon-derivative security10b5-1: —8,439$4.18$35,284.00357,720Nov 2, 2026Nov 3, 2026Source record
Horan ChristopherChief Tech Operations OfficerOpen-market saleNon-derivative security10b5-1: —10,423$4.18$43,580.00302,321Nov 2, 2026Nov 3, 2026Source record
Aslan FredCEOOpen-market saleNon-derivative security10b5-1: —62,178$4.18$259,972.001,457,428Nov 2, 2026Nov 3, 2026Source record
Banerjee SubhashisChief Medical OfficerOpen-market saleNon-derivative security10b5-1: —1,110$4.18$4,641.00168,738Nov 2, 2026Nov 3, 2026Source record

Review the entire collected insider disclosure history with a free account.

Full collected history is available here after sign-in, separate from the public 12-month window. It is not an exhaustive trading history.

Notable recent activity

The largest open-market transaction by reported value in the public window was an open-market sale by Aslan Fred on Nov 17, 2026: $468,532.00, involving 119,771 shares. Reported price: $3.91.

0 public-window transactions explicitly indicate a 10b5-1 plan. A missing indication is not proof that a transaction was discretionary. Prices and values are shown only when reported; unavailable fields are not filled with zero.

ARTV research questions

Are ARTV insiders buying or selling?

Collected disclosures show 0 open-market purchases and 9 sales with transaction dates in the trailing 30 days ending Nov 22, 2026. Net reported purchase less sale value is -$987,430.00. The latest collected disclosure data is as of Nov 18, 2026. These counts do not represent every insider action.

How many ARTV insiders reported recent trades?

5 distinct insiders appear in collected disclosures for transaction dates in the trailing 30 days ending Nov 22, 2026. The latest collected Form 4 was filed on Nov 18, 2026. A filing date is not the transaction date.

How much ARTV insider trading history is public?

This page shows 9 collected transactions dated in the trailing 12 months ending Nov 22, 2026. 0 older collected transactions are summarized outside this window and can be viewed here after sign-in. This is collected disclosure coverage, not exhaustive history; 10b5-1 plan status and derivative securities are labeled per record.

Read the disclosure, then the context

Insider data covers the trailing 12 months on public tables. Congressional tables cover all saved disclosures. Neither is an exhaustive history. Form 4 filing dates and congressional disclosure dates may differ from trade dates. Congressional amounts are ranges, not estimated dollar totals. Disclosure activity alone does not establish intent or predict returns.

From disclosure to research

Keep ARTV on your research desk.

Create a workspace for filing analysis and research notes. Filing-alert availability depends on your plan. Review the plan features separately; opening the plans page does not create an alert.